Current Report Filing (8-k)
09 September 2019 - 1:01PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event
reported):
September 9, 2019
____________________________
ChineseInvestors.com,
Inc.
(Exact name of registrant as specified
in its charter)
____________________________
Indiana
|
000-54207
|
35-2089868
|
(State of Organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification Number)
|
|
|
|
227 W. Valley Blvd. #208A, San Gabriel, CA
|
|
91776
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(626) 589-2468
(Registrant’s telephone number, including
area code)
Check appropriate box below if the Form 8-K filing is intended
to simultaneously satisfying the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
☐ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark
whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐
If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events
The Company issued a press release
in which it announced the launch of six new hemp infused skin care products through its CBD Biotech subsidiary in China in connection
with CBD Biotech’s long-term strategic plans to the expand its hemp/CBD skincare offerings.
Item 9.01 Financial Statements and Exhibits
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
Date: September 9, 2019
ChineseInvestors.com, Inc.
By: /s/ Wei Wang
Name: Wei Wang
Title: Chief Executive Officer